COLLEGIUM PHARMACEUTICAL, INC - 10-Q Filing

Collegium Pharmaceutical reports Q3 2026 financial results including product revenue breakdowns for Belbuca, Xtampza ER, and Jornay PM.

SEC EDGAR ·

Tickers: $COLL

Read the full article at SEC EDGAR

More Regulatory news